One of the most widely used commercial bifidobacteria, notable for unusual tolerance of acid and bile, which is why it survives both manufacture and the stomach better than most.
BB-12 is included in a very large number of yoghurts, infant formulas and supplements, and it has an unusually large safety record as a result. Its efficacy record is more modest: trials report small improvements in stool frequency and consistency, some reduction in gastrointestinal symptoms, and inconsistent findings for infection incidence. It is best understood as a well-characterised, well-tolerated organism with a modest and generally honestly reported effect, rather than as a strain with a headline result.
Sold as
Capsule, Sachet, Yoghurt culture, Infant formula ingredient, Chewable
Standardised to
CFU of strain BB-12 per dose, commonly 1–10 billion — a product without this marker may not resemble what was studied.
Also known as
BB-12, B. lactis BB-12
Regulation: Widely used in foods and supplements with a substantial safety dossier. No authorised health claims in the EU; sold in the US as a dietary supplement without pre-market efficacy review.
What the research used
The amounts, forms and durations published trials of Bifidobacterium lactis BB-12 actually administered.
These are the amounts published trials administered — not a recommendation, and not a dose to copy. Trial participants were screened, supervised and given a characterised preparation. What is in a retail bottle is frequently not what was studied, and the amount that suits one person is not general advice.
Studied for Bowel habit and stool consistency
1–10 billion CFU
Limited
Capsule, sachet or fermented milk, daily · 2–8 weeks
Dose-ranging work suggests effects on defecation frequency at around 10 billion CFU/day, with small absolute changes. Many trials use it alongside other strains, which complicates attribution.
This is general information about food, not medical advice. It cannot diagnose, treat or replace guidance from a clinician who knows your history.
When it was taken
Each window says whether a trial compared it against an alternative, or whether it is convention and pharmacology. Most timing advice is the second kind.
None of the timings below were directly compared in a trial. They reflect how the research happened to dose, or what the pharmacology implies — which is not the same as a timing being better.
🍽️With food
Not enough
BB-12 is unusually acid- and bile-tolerant, so the food effect on survival is smaller than for most probiotics. Taking it with food remains the convention and has not been tested against alternatives clinically.
Timing was not directly compared. This reflects convention or how the compound behaves in the body, not a trial showing this window works better.
The evidence in depth
Best supported: Limited
What each association actually rests on, and the papers behind it. A rating describes the state of the research, not how promising the supplement sounds. How we rate evidence.
Trials report small increases in defecation frequency and softer stools with BB-12, most clearly in people with infrequent bowel movements at baseline. The changes are modest and the endpoints self-reported.
Limited evidence. Early human work, or mostly lab and animal research.
Some trials report reductions in bloating and abdominal discomfort, often in blends where BB-12 is one of several organisms. Attributing the effect to this strain alone is usually not possible.
Limited evidence. Early human work, or mostly lab and animal research.
Studies of BB-12 and respiratory or gastrointestinal infections in infants and adults report inconsistent results. There is not enough dependable evidence to support an immune claim.
Not enough evidence. Not enough human research to say anything useful yet.
Randomised controlled trial · FEMS immunology and medical microbiology · 2008 · PMID 18336547
Deep research mode adds each paper’s own conclusion and stated limitations.
Things to know
Interactions, contraindications and dose limits, most serious first. Concentrated extracts interact with medication in ways the whole plant does not, so this section carries more weight here than it does on a food page.
Avoid
Immunocompromise, central lines and critical illness
The general live-culture contraindication applies despite this strain’s good safety record. Case reports of bifidobacterial bacteraemia exist in preterm and immunosuppressed patients.
Worth knowing
Usually studied in blends
BB-12 appears in many multi-strain products and fermented foods, so trial results often cannot be attributed to it specifically.
Allergy
Dairy carriers
Frequently supplied in milk-based products or grown on dairy media. Relevant to milk allergy rather than lactose intolerance.
In the food catalogue
The whole-food form, where one exists. The evidence for a concentrated extract rarely transfers to the food, or the other way round — these are cross-links, not equivalents.